NNNN
HealthcareAnbio Biotechnology Class A Ordinary Shares · Medical - Instruments & Supplies · $1B
What is Anbio Biotechnology Class A Ordinary Shares?
Anbio Biotechnology is a small-cap diagnostics company headquartered in Frankfurt am Main, Germany, focused on in vitro diagnostics products sold across multiple global regions. It targets both consumer and clinical testing markets with a range of rapid and laboratory-grade solutions.
Anbio Biotechnology develops and distributes in vitro diagnostics products, including rapid antigen tests and more advanced immunoassay and molecular testing platforms. Its products serve over-the-counter consumers, point-of-care testing settings, and traditional laboratory environments. The company sells into the European Union, Asia Pacific, North America, South America, Africa, and other international markets, positioning itself as a globally distributed diagnostics supplier rather than a single-region operator.
Anbio Biotechnology was incorporated in 2021 and is headquartered in Frankfurt am Main, Germany.
- SARS-CoV-2 antigen rapid tests for consumer and clinical use
- SARS-CoV-2 and influenza A/B combination rapid tests
- Lateral flow immunoassay diagnostic products
- Fluorescence and chemiluminescence immunoassay platforms
- Loop-mediated isothermal amplification and RT-PCR products
Is NNNN a Good Stock to Buy?
UQS Score rates NNNN as Below Average overall.
The most notable positive in Anbio's profile is its Risk pillar, which scores Strong — suggesting the company carries a relatively manageable risk profile compared to many small-cap peers in the diagnostics space. This may reflect balance sheet characteristics or limited leverage at this stage of the company's development.
The Growth and Moat pillars both register as Weak, pointing to limited competitive differentiation and constrained expansion momentum. Valuation is rated Elevated, meaning the current market price may not offer a compelling entry point relative to fundamentals.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does NNNN pay dividends?
No — Anbio Biotechnology Class A Ordinary Shares does not currently pay a dividend.
Anbio Biotechnology does not currently pay a dividend. As a recently incorporated small-cap company in the diagnostics sector, capital is more likely directed toward building out product lines, expanding distribution, and funding operations. Investors seeking income from this holding will need to look elsewhere, as reinvestment rather than distribution appears to be the current priority.
When does NNNN report earnings?
Anbio Biotechnology reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Given the Weak Growth pillar rating, recent earnings periods have not demonstrated the kind of revenue or profitability expansion that would signal a strong upward trajectory. The Quality pillar sitting at Neutral suggests results have been neither consistently strong nor materially deteriorating.
For the most recent quarter's results and guidance, visit Anbio Biotechnology's official investor relations page.
NNNN Price History
+311.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Anbio Biotechnology Class A Ordinary Shares?
Based on Anbio Biotechnology Class A Ordinary Shares's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
NNNN Long-term Outlook
Anbio's fundamental outlook reflects the challenges common to smaller diagnostics companies operating in a post-pandemic environment where demand for COVID-related testing has normalized. The Weak Growth pillar suggests the company has not yet demonstrated a clear path to meaningful revenue expansion. The Strong Risk rating provides some reassurance that near-term financial distress is less of an immediate concern, but the Elevated Valuation pillar indicates the market may already be pricing in optimistic scenarios that the current fundamentals do not fully support.
Growth drivers
- Expansion into underserved international diagnostics markets across Africa and South America
- Broadening product portfolio beyond COVID testing into multi-pathogen rapid diagnostics
- Growing point-of-care testing adoption in decentralized healthcare settings globally
Key risks
- Sustained decline in COVID-related test demand without sufficient replacement revenue
- Elevated Valuation creating downside risk if growth expectations are not met
- Limited competitive moat in a crowded IVD market with larger, better-resourced rivals
NNNN vs Peers
Anbio Biotechnology operates in the broader healthcare and diagnostics space alongside a range of companies with differing business models and market positions.
Azenta focuses on life sciences sample management and genomics services, operating further upstream in the research and biobanking workflow compared to Anbio's consumer and point-of-care diagnostics focus.
STAAR Surgical specializes in implantable lenses for vision correction, representing a surgical device niche that differs significantly from Anbio's rapid and laboratory diagnostics product lines.
Kestra Medical develops wearable cardioverter defibrillators, placing it in the cardiac monitoring segment rather than the infectious disease and immunoassay diagnostics space where Anbio competes.
Frequently Asked Questions
What does Anbio Biotechnology do?
Anbio Biotechnology develops and sells in vitro diagnostics products, including rapid antigen tests for COVID-19 and influenza, as well as immunoassay and molecular testing platforms. It serves over-the-counter consumers, point-of-care settings, and laboratory markets across multiple continents.
Does NNNN pay dividends?
No, Anbio Biotechnology does not currently pay a dividend. As a small-cap company in an early stage of its commercial development, available capital appears to be directed toward operations and product expansion rather than shareholder distributions.
When does NNNN report earnings?
Anbio Biotechnology follows a quarterly earnings reporting cadence standard for US-listed companies. For specific upcoming report dates and the latest financial results, check the company's investor relations page directly.
Is NNNN a good stock to buy?
UQS Score rates NNNN as Below Average, reflecting Weak Growth and Moat pillars alongside an Elevated Valuation. The Strong Risk pillar is a relative positive. Whether it fits your portfolio depends on your own risk tolerance and investment criteria — the full UQS pillar breakdown is available to Pro members.
Is NNNN overvalued?
The UQS Valuation pillar for NNNN is rated Elevated, suggesting the current market price may be high relative to the company's underlying fundamentals. This does not guarantee price decline, but it does indicate limited margin of safety at current levels based on the UQS framework.
How does NNNN compare to its competitors?
Anbio operates in a different niche than peers like Azenta, STAAR Surgical, and Kestra Medical, each of which focuses on distinct healthcare subsectors. Within the IVD diagnostics space specifically, Anbio faces competition from larger, more established players with broader product portfolios and stronger distribution networks.
What is NNNN's market cap bracket?
Anbio Biotechnology is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to mid-cap or large-cap peers, but may also offer different growth dynamics for investors comfortable with that profile.
Who founded Anbio Biotechnology?
Anbio Biotechnology was incorporated in 2021 and is headquartered in Frankfurt am Main, Germany. Detailed founding and leadership information is publicly available through the company's official filings and investor relations materials.
Is NNNN a long-term quality investment?
From a long-term quality perspective, the UQS framework currently rates NNNN as Below Average, with Weak scores on both Growth and Moat — two pillars that matter most for sustained long-term value creation. The Strong Risk pillar offers some stability, but the overall profile warrants careful consideration before a long-term commitment.
What is the main competitive advantage of Anbio Biotechnology?
The UQS Moat pillar for Anbio is rated Weak, indicating limited identifiable competitive advantages relative to peers at this time. The company's international distribution reach across multiple regions may represent a developing strength, but it has not yet translated into a durable moat by UQS measures.
What sector does NNNN belong to?
Anbio Biotechnology operates in the Healthcare sector, specifically within the in vitro diagnostics segment. It develops rapid tests and immunoassay platforms serving consumer, point-of-care, and laboratory markets globally. You can explore more [healthcare sector stocks](/sector/healthcare) on UQS Score.
Unlock Full NNNN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare NNNN against sector peers side by side
- ✓Track quality score changes over time
- ✓Screen for stocks with stronger Moat and Growth ratings
- ✓Get the full analyst-grade view in one dashboard
Pro Analysis
NNNN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 51.4 | 74.9 | 22.0 | 71.3 | 82.4 | 3.6 | +14.4 |
| Apr 18, 2026 | 37.0 | 53.3 | 22.0 | 28.2 | 82.4 | 1.4 | -0.2 |
| Apr 13, 2026 | 37.2 | 53.3 | 22.0 | 28.2 | 82.4 | 2.4 | +4.5 |
| Apr 11, 2026 | 32.7 | 51.4 | 22.0 | 8.0 | 82.4 | 2.4 | 0.0 |
| Apr 9, 2026 | 32.7 | 51.5 | 22.0 | 8.0 | 82.4 | 2.5 | 0.0 |
| Apr 8, 2026 | 32.7 | 51.4 | 22.0 | 8.0 | 82.4 | 2.4 | 0.0 |
| Apr 2, 2026 | 32.7 | 51.5 | 22.0 | 8.0 | 82.4 | 2.5 | — |
NNNN — Pillar Breakdown
Quality
— 74.9/100 (25%)Anbio Biotechnology Class A Ordinary Shares shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 71.3/100 (20%)Anbio Biotechnology Class A Ordinary Shares demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 82.4/100 (15%)Anbio Biotechnology Class A Ordinary Shares carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 3.0/100 (15%)Anbio Biotechnology Class A Ordinary Shares appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
Enterprise value multiple relative to sector median.
Moat
— 22/100 (25%)Anbio Biotechnology Class A Ordinary Shares operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NNNN.
Score Composition
Financial Data
More Stock Analysis
How is the NNNN UQS Score Calculated?
The UQS (Unified Quality Score) for Anbio Biotechnology Class A Ordinary Shares is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Anbio Biotechnology Class A Ordinary Shares's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Anbio Biotechnology Class A Ordinary Shares is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.